TransMedics Group, Inc. TMDX
Set alert
At close
Pre-market · Nov 3, 6:17 AM ET
- YTD
- -45.20%
- 1 year
- -49.32%
- Open
- 66.47
- Prev close
- 65.99
- Mkt cap
- 2.31B
- Vol
- 689.58K
- Avg vol
- 837.49K
- EPS
- 3.86
- P/E
- 17.27
- Div yield
- 0.00%
More statistics
- Low
- 65.84
- High
- 68.66
- Forward P/E
- 29.58
- Beta
- 2.10
- Short ratio
- 11.14
- Inst. own
- 104.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 81.65
- 200-d avg
- 94.48
- 1y target
- 98.73
6M chart
Events in this range
- May 5, 2026Earnings: 0.3; estimate 0.62; surprise -51.61%
- Aug 3, 2026Rating: Needham · Buy → Buy
- Aug 4, 2026Earnings: 0.44; estimate 0.4955; surprise -11.2%
- Aug 5, 2026Rating: Piper Sandler · Overweight → Overweight
- Aug 5, 2026Rating: UBS · Neutral → Neutral
- Sep 8, 2026Rating: TD Cowen · Buy → Buy
- Oct 7, 2026Rating: Barclays · — → Overweight
- Oct 13, 2026Rating: Canaccord Genuity · Buy → Buy
Signals (14)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| RSI: Oversold | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Jul 13, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 7, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 30, 2026 | 4 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| RSI: Oversold | May 6, 2026 | 6 months ago |
Key statistics
- Market cap
- 2.30B
- Enterprise value
- 2.68B
- Trailing P/E
- 17.27
- Forward P/E
- 29.58
- PEG ratio
- 0.57
- Price / sales
- 3.45
- Price / book
- 4.46
- EPS (TTM)
- 3.86
- Beta
- 2.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 22.69%
- Revenue (TTM)
- 668.47M
- Revenue growth
- 20.70%
- Free cash flow
- 44.50M
- Total cash
- 472.68M
- Total debt
- 867.72M
- Return on equity
- 36.29%
- Shares outstanding
- 34.56M
- Short % of float
- 39.37%
- 50-day average
- 81.65
- 200-day average
- 94.48
Analyst view
Consensus: buy
- Target (low)
- 65.00
- Target (mean)
- 98.73
- Target (high)
- 125.00
- Strong buy3
- Buy6
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.2934.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.2976 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 0.4955 | 0.44 | -0.06 | -11.20% |
| May 5, 2026 | Mar 31, 2026 | 0.62 | 0.30 | -0.32 | -51.61% |
| Feb 24, 2026 | Dec 31, 2025 | 0.41 | 0.57 | +0.16 | +39.02% |
| Oct 29, 2025 | Sep 30, 2025 | 0.37 | 0.66 | +0.29 | +78.38% |
| Jul 30, 2025 | Jun 30, 2025 | 0.48 | 0.92 | +0.44 | +91.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Sep 8, 2026 | TD Cowen | reit | Buy | Buy |
| Aug 5, 2026 | UBS | main | Neutral | Neutral |
| Aug 5, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Aug 3, 2026 | Needham | main | Buy | Buy |
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- transmedics.com
News
- TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at Upcoming Investor Conferences
- TransMedics selects Gogo Galileo HDX for nationwide organ transport fleet
- Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $94
- Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120
Your note
Sign in to keep a note on TMDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CECERE GIOVANNI | Officer | Stock Award(Grant) | Feb 17, 2026 | 19,057 |
| CORCORAN NICHOLAS | Officer | Stock Award(Grant) | Jul 9, 2026 | 41,558 |
| FORSYTH MATTHEW S | General Counsel | Stock Award(Grant) | May 18, 2026 | 15,409 |
| GUNDERSON THOMAS JAMES | Director | Sale | Jun 14, 2026 | 16,642 |
| HASSANEIN WALEED H | Chief Executive Officer | Stock Award(Grant) | Jul 9, 2026 | 666,102 |
| HERNANDEZ GERARDO | Chief Financial Officer | Stock Award(Grant) | Jul 9, 2026 | 31,935 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.19% | 5,596,549 | 373.12M | Jun 29, 2026 |
| FMR, LLC | 14.85% | 5,133,328 | 342.24M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.60% | 1,933,989 | 128.94M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.33% | 1,497,600 | 99.84M | Jun 29, 2026 |
| State Street Corporation | 4.11% | 1,420,421 | 94.70M | Jun 29, 2026 |
| Nomura Asset Management International Inc | 2.63% | 910,495 | 60.70M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.97% | 2,064,603 | 137.65M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,038,890 | 69.26M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.56% | 885,083 | 59.01M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.18% | 752,168 | 50.15M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.10% | 726,130 | 48.41M | Jul 30, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 1.79% | 617,377 | 41.16M | Aug 30, 2026 |